Core Viewpoint - BeiGene (ONC.US) experienced a significant increase of over 9%, closing at $334.20, following the release of its financial report for the first half of 2025, which showed a total revenue of 17.518 billion yuan, a year-on-year growth of 46.03% [1] Financial Performance - The total revenue for the first half of 2025 reached 17.518 billion yuan, with product revenue accounting for 17.36 billion yuan, reflecting a year-on-year increase of 45.8% [1] - The company achieved a net profit of 450 million yuan, marking its first profitable quarter of the year [1] Product Performance - The growth in product revenue was driven by sales increases of self-developed products, namely Brukinsa (Zebutinib capsules) and Tislelizumab (anti-PD-1 monoclonal antibody), as well as increased sales from Amgen licensed products [1] - Brukinsa demonstrated outstanding performance, becoming the leading BTK inhibitor in both the U.S. and global markets [1] Sales Breakdown - Global sales of Brukinsa reached 12.527 billion yuan, representing a year-on-year growth of 56.2% [1] - In the U.S. market, sales of Brukinsa amounted to 8.958 billion yuan, with a year-on-year increase of 51.7% [1] - Brukinsa has rapidly gained adoption among patients and physicians in the U.S. due to its best-in-class clinical characteristics, making it the largest and fastest-growing product in the market [1]